CN107001278B - 四氢异喹啉衍生物 - Google Patents
四氢异喹啉衍生物 Download PDFInfo
- Publication number
- CN107001278B CN107001278B CN201580064005.3A CN201580064005A CN107001278B CN 107001278 B CN107001278 B CN 107001278B CN 201580064005 A CN201580064005 A CN 201580064005A CN 107001278 B CN107001278 B CN 107001278B
- Authority
- CN
- China
- Prior art keywords
- methyl
- dihydroisoquinolin
- dichlorophenyl
- ethanone
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14188174.8 | 2014-10-08 | ||
| EP14188174 | 2014-10-08 | ||
| PCT/EP2015/073053 WO2016055479A1 (en) | 2014-10-08 | 2015-10-06 | Tetrahydroisoquinoline derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107001278A CN107001278A (zh) | 2017-08-01 |
| CN107001278B true CN107001278B (zh) | 2020-11-24 |
Family
ID=51790569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201580064005.3A Expired - Fee Related CN107001278B (zh) | 2014-10-08 | 2015-10-06 | 四氢异喹啉衍生物 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10105359B2 (enExample) |
| EP (1) | EP3204359B1 (enExample) |
| JP (1) | JP6622299B2 (enExample) |
| CN (1) | CN107001278B (enExample) |
| BR (1) | BR112017007123B1 (enExample) |
| CA (1) | CA2963951C (enExample) |
| CY (1) | CY1123417T1 (enExample) |
| DK (1) | DK3204359T3 (enExample) |
| EA (1) | EA035544B1 (enExample) |
| ES (1) | ES2821821T3 (enExample) |
| HR (1) | HRP20201469T1 (enExample) |
| HU (1) | HUE050664T2 (enExample) |
| LT (1) | LT3204359T (enExample) |
| PL (1) | PL3204359T3 (enExample) |
| PT (1) | PT3204359T (enExample) |
| RS (1) | RS60933B1 (enExample) |
| SI (1) | SI3204359T1 (enExample) |
| WO (1) | WO2016055479A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11612599B2 (en) * | 2016-02-25 | 2023-03-28 | Asceneuron Sa | Glycosidase inhibitors |
| EP3442945B1 (en) | 2016-04-13 | 2020-07-08 | UCB Biopharma SRL | Tetrahydroisoquinoline derivatives |
| CN107698433A (zh) * | 2017-09-12 | 2018-02-16 | 潍坊滨海石油化工有限公司 | 苯乙酸的制备方法 |
| US20200369675A1 (en) * | 2017-12-01 | 2020-11-26 | UCB Biopharma SRL | Imaging Agents |
| TWI725408B (zh) * | 2018-04-20 | 2021-04-21 | 美商美國禮來大藥廠 | 多巴胺d1受體正向異位調節劑 |
| SG11202112539XA (en) | 2019-07-01 | 2021-12-30 | UCB Biopharma SRL | A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator |
| MX2021015873A (es) * | 2019-07-01 | 2022-02-03 | UCB Biopharma SRL | Un derivado de tetrahidroisoquinolina sustituido como modulador alosterico positivo de d1. |
| EP4138792A4 (en) * | 2020-04-24 | 2024-04-24 | The Regents of the University of California | NURR1 RECEPTOR MODULATORS AND USES THEREOF |
| CN111943930B (zh) * | 2020-08-25 | 2022-11-01 | 南京三元阳普医药科技有限公司 | Lasmiditan的合成工艺 |
| ES2976784T3 (es) * | 2020-10-07 | 2024-08-08 | Lilly Co Eli | Derivados de fenil-3,4-dihidroisoquinolin-2(1H)-il-etan-1-ona como moduladores alostéricos positivos del receptor de dopamina D1 |
| EP4267555A1 (en) | 2020-12-03 | 2023-11-01 | UCB Biopharma SRL | Octahydroisoquinolinyl derivatives |
| EP4262756A1 (en) * | 2020-12-18 | 2023-10-25 | UCB Biopharma SRL | Amorphous solid dispersions |
| EP4263517B1 (en) * | 2020-12-18 | 2024-10-02 | UCB Biopharma SRL | A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator |
| US20240083925A1 (en) * | 2020-12-18 | 2024-03-14 | UCB Biopharma SRL | Prodrugs of 2-(3,5-Dichloro-1-methyl-indazol-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethanone |
| CA3202106A1 (en) | 2020-12-18 | 2022-06-23 | Adrian Hall | Dihydroisoquinolinyl derivatives |
| US20240299375A1 (en) | 2021-03-08 | 2024-09-12 | Eli Lilly And Company | Use of mevidalen and other d1 positive allosteric modulators in the treatment of hallucinations and dementia-related psychosis |
| MX2023010542A (es) | 2021-03-09 | 2023-11-24 | Lilly Co Eli | Uso de mevidaleno y otros moduladores alostéricos positivos d1 para ralentizar la progresión de la enfermedad de parkinson. |
| CN114671810B (zh) * | 2022-03-21 | 2024-03-22 | 济南鸿湾生物技术有限公司 | 一种咪唑苯脲的制备方法 |
| CN115611768B (zh) * | 2022-11-14 | 2024-03-05 | 郑州大学 | 一种3,4-二氯苯腈的合成方法 |
| CN118724764B (zh) * | 2024-06-07 | 2025-11-18 | 绍兴文理学院 | 一种芳基伯磺酰胺类化合物的制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4766131A (en) * | 1980-10-17 | 1988-08-23 | Pennwalt Corporation | 2-amino (or hydroxy) phenethyl-1,2,3,4-tetrahydroisoquinolines as analgesics |
| IL162310A0 (en) * | 2001-12-19 | 2005-11-20 | Lundbeck & Co As H | 3,4-Dihydro-1h-isoquinoloin-2-yl-derivatives |
| JP4685861B2 (ja) * | 2004-04-29 | 2011-05-18 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | ドーパミンアゴニストとしての３−ピペリジニルイソクロマン−５−オール |
| CA2679735A1 (en) | 2007-03-01 | 2008-09-12 | Janssen Pharmaceutica N.V. | Tetrahydroisoquinoline compounds as modulators of the histamine h3 receptor |
-
2015
- 2015-10-06 HU HUE15775688A patent/HUE050664T2/hu unknown
- 2015-10-06 HR HRP20201469TT patent/HRP20201469T1/hr unknown
- 2015-10-06 DK DK15775688.3T patent/DK3204359T3/da active
- 2015-10-06 RS RS20201139A patent/RS60933B1/sr unknown
- 2015-10-06 EP EP15775688.3A patent/EP3204359B1/en active Active
- 2015-10-06 ES ES15775688T patent/ES2821821T3/es active Active
- 2015-10-06 CN CN201580064005.3A patent/CN107001278B/zh not_active Expired - Fee Related
- 2015-10-06 LT LTEP15775688.3T patent/LT3204359T/lt unknown
- 2015-10-06 EA EA201790785A patent/EA035544B1/ru not_active IP Right Cessation
- 2015-10-06 PT PT157756883T patent/PT3204359T/pt unknown
- 2015-10-06 BR BR112017007123-1A patent/BR112017007123B1/pt not_active IP Right Cessation
- 2015-10-06 WO PCT/EP2015/073053 patent/WO2016055479A1/en not_active Ceased
- 2015-10-06 US US15/517,795 patent/US10105359B2/en active Active
- 2015-10-06 CA CA2963951A patent/CA2963951C/en active Active
- 2015-10-06 JP JP2017518989A patent/JP6622299B2/ja active Active
- 2015-10-06 SI SI201531348T patent/SI3204359T1/sl unknown
- 2015-10-06 PL PL15775688.3T patent/PL3204359T3/pl unknown
-
2020
- 2020-09-30 CY CY20201100923T patent/CY1123417T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA201790785A1 (ru) | 2017-10-31 |
| EP3204359B1 (en) | 2020-07-01 |
| CY1123417T1 (el) | 2021-12-31 |
| JP6622299B2 (ja) | 2019-12-18 |
| CA2963951C (en) | 2023-02-28 |
| BR112017007123B1 (pt) | 2023-01-31 |
| LT3204359T (lt) | 2020-10-12 |
| US10105359B2 (en) | 2018-10-23 |
| PT3204359T (pt) | 2020-09-24 |
| HUE050664T2 (hu) | 2020-12-28 |
| JP2017530185A (ja) | 2017-10-12 |
| ES2821821T3 (es) | 2021-04-27 |
| SI3204359T1 (sl) | 2020-10-30 |
| CA2963951A1 (en) | 2016-04-14 |
| WO2016055479A1 (en) | 2016-04-14 |
| BR112017007123A2 (pt) | 2017-12-19 |
| EA035544B1 (ru) | 2020-07-03 |
| PL3204359T3 (pl) | 2021-03-22 |
| US20170304292A1 (en) | 2017-10-26 |
| RS60933B1 (sr) | 2020-11-30 |
| CN107001278A (zh) | 2017-08-01 |
| EP3204359A1 (en) | 2017-08-16 |
| DK3204359T3 (da) | 2020-09-14 |
| HRP20201469T1 (hr) | 2020-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107001278B (zh) | 四氢异喹啉衍生物 | |
| JP6941241B2 (ja) | 縮合環化合物 | |
| CN105683188B (zh) | 作为fgfr4抑制剂的稠环二环吡啶基衍生物 | |
| TW202110837A (zh) | 氫化吡啶并嘧啶類衍生物、其製備方法及其在醫藥上的應用 | |
| CN112119075A (zh) | 稠环化合物 | |
| CN103097375B (zh) | Ccr2的环己基-氮杂环丁烷拮抗剂 | |
| CN104703988B (zh) | 新的三唑并吡嗪衍生物及其用途 | |
| WO2022194269A1 (zh) | 新型egfr降解剂 | |
| CN114096546A (zh) | 用作mcl-1抑制剂的大环螺环衍生物 | |
| RU2783706C1 (ru) | Соединения с конденсированными кольцами | |
| HK40057478B (zh) | Hpk1抑制剂及其使用方法 | |
| HK40041215A (en) | Fused ring compounds | |
| BR122024023999A2 (pt) | Compostos e composição farmacêutica | |
| HK40063823A (en) | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | |
| HK40041215B (zh) | 稠环化合物 | |
| HK40040938A (en) | Fused ring compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20201124 |